Inicio › Síndromes mielodisplásicos › Ohio › Columbus
Ensayos clínicos de Síndromes mielodisplásicos en Columbus, OH
14 estudios para Síndromes mielodisplásicos buscan participantes en centros de Columbus y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
ReclutandoFase 1/2
- The Ohio State University, Columbus
Collection of Tissue Samples for Cancer Research
ReclutandoEstudio observacional
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
ReclutandoFase 1
- Ohio State University, The James Comprehensive Cancer, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
ReclutandoFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Nationwide Children's Hospital, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
ReclutandoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutandoFase 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
ReclutandoFase 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutandoFase 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
ReclutandoEstudio observacional
- The Ohio State University Medical Center, Columbus
Más información sobre Síndromes mielodisplásicos en MedlinePlus
Ensayos de Síndromes mielodisplásicos en otras ciudades
- Houston, TX43 estudios
- Baldwin Park, CA26 estudios
- New York City, NY21 estudios
- Seattle, WA21 estudios
- Washington, DC20 estudios
- Tampa, FL19 estudios
- Boston, MA19 estudios
- Miami, FL17 estudios
- Durham, NC14 estudios
- St. Louis, MO13 estudios
- Atlanta, GA13 estudios
- Chicago, IL13 estudios
Otros estudios en Columbus
- Cáncer de pulmón de células no pequeñas57 estudios
- Cáncer de seno40 estudios
- Cáncer de ovario39 estudios
- Cáncer (todos los tipos)38 estudios
- Cáncer de pulmón37 estudios
- Leucemia mielógena aguda35 estudios
- Leucemia linfocítica crónica28 estudios
- Cáncer metastásico27 estudios
- Cáncer de endometrio25 estudios
- Cáncer de próstata24 estudios
- Mieloma múltiple24 estudios
- Cáncer del colon y del recto24 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.